Fig. 5: Impact of dose on immunogenicity of VLP variants. | Nature Communications

Fig. 5: Impact of dose on immunogenicity of VLP variants.

From: Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response

Fig. 5

A–D Immunogenicity of TLR agonist RNA40 encapsidated chimeric NDV VLP variants expressing the indicated stabilized HIV-1 envelope protein with or without AS01 adjuvant and IM administered at high doses (500 μg). E Heatmap of neutralization activity (ID50) in rabbit serum against a panel of 10 HIV-1 Env pseudoviruses from clades (A–C), and SIVmac256. Blue arrows indicate the week of IM-administered immunization. Serum neutralizing antibody titers (ID50) of each rabbit (n = 6) are shown in dots, and the median value for each time point is connected with a solid line.

Back to article page